References
- Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296. doi:https://doi.org/10.3322/caac.21456.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30. doi:https://doi.org/10.3322/caac.21590.
- Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 2017;28(suppl_8):viii61–viii65. doi:https://doi.org/10.1093/annonc/mdx443.
- Bian X, Xia J, Wang K, Wang Q, Yang L, Wu W, et al. The effects of a prior malignancy on the survival of patients with ovarian cancer: a population-based study. J Cancer. 2020;11(21):6178–6187. doi:https://doi.org/10.7150/jca.46584.
- Lim MC, Won Y-J, Lim J, Salehi T, Yoo CW, Bristow RE. Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study. BMC Cancer. 2018;18(1):800. doi:https://doi.org/10.1186/s12885-018-4700-3.
- Coleman MP, Bell CM, Fraser P. Second primary malignancy after Hodgkin’s disease, ovarian cancer and cancer of the testis: a population-based cohort study. Br J Cancer. 1987;56(3):349–355. doi:https://doi.org/10.1038/bjc.1987.201.
- Hung Y-P, Liu C-J, Hu Y-W, Chen M-H, Li C-P, Yeh C-M, et al. Secondary primary malignancy risk in patients with ovarian cancer in Taiwan: a nationwide population-based study. Medicine. 2015;94(38):e1626. doi:https://doi.org/10.1097/MD.0000000000001626.
- Dent SF, Klaassen D, Pater JL, Zee B, Whitehead M. Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada–Clinical Trials Group (NCIC-CTG). Ann Oncol. 2000;11(1):65–68. doi:https://doi.org/10.1023/A:1008356806417.
- Bergfeldt K, Silfverswärd C, Einhorn S, Hall P. Overestimated risk of second primary malignancies in ovarian cancer patients. Eur J Cancer. 2000;36(1):100–105. doi:https://doi.org/10.1016/S0959-8049(99)00244-0.
- Kanninen TT, Nasioudis D, Sisti G, Holcomb K, Di Tommaso M, Khalil S, et al. Epidemiology of second primary tumors in women with ovarian cancer. Int J Gynecol Cancer. 2017;27(4):659–667. doi:https://doi.org/10.1097/IGC.0000000000000950.
- Li Z, Wang K, Shi Y, Zhang X, Wen J. Incidence of second primary malignancy after breast cancer and related risk factors-Is breast-conserving surgery safe? A nested case-control study. Int J Cancer. 2020;146(2):352–362. doi:https://doi.org/10.1002/ijc.32259.
- Suk R, Mahale P, Sonawane K, Sikora AG, Chhatwal J, Schmeler KM, et al. Trends in risks for second primary cancers associated with index human papillomavirus-associated cancers. JAMA Netw Open. 2018;1(5):e181999. doi:https://doi.org/10.1001/jamanetworkopen.2018.1999.
- Goldfarb M, Rosenberg AS, Li Q, Keegan THM. Impact of latency time on survival for adolescents and young adults with a second primary malignancy. Cancer. 2018;124(6):1260–1268. doi:https://doi.org/10.1002/cncr.31170.
- Liu Y, Zhang P, Zhang Y, Zheng L, Xu W, Hou D, et al. Clinical characteristics and overall survival nomogram of second primary malignancies after prostate cancer, a SEER population-based study. Sci Rep. 2021;11(1):1293. doi:https://doi.org/10.1038/s41598-020-80534-4.
- Hong J, Wei R, Nie C, Leonteva A, Han X, Du X, et al. The risk and prognosis of secondary primary malignancy in lung cancer: a population-based study. Future Oncol. 2021;17(33):4497–4509. doi:https://doi.org/10.2217/fon-2021-0045.
- Wei JL, Jiang YZ, Shao ZM. Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study. Int J Clin Oncol. 2019;24(8):934–940. doi:https://doi.org/10.1007/s10147-019-01430-0.
- Fletcher SA, Marchese M, Cole AP, Mahal BA, Friedlander DF, Krimphove M, et al. Geographic distribution of racial differences in prostate cancer mortality. JAMA Netw Open. 2020;3(3):e201839. doi:https://doi.org/10.1001/jamanetworkopen.2020.1839.
- Tomaszewski JJ, Uzzo RG, Egleston B, Corcoran AT, Mehrazin R, Geynisman DM, et al. Coupling of prostate and thyroid cancer diagnoses in the United States. Ann Surg Oncol. 2015;22(3):1043–1049. doi:https://doi.org/10.1245/s10434-014-4066-y.
- Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–1370. doi:https://doi.org/10.1200/JCO.2007.12.9791.
- Soerjomataram I, Coebergh JW. Epidemiology of multiple primary cancers. Methods in Mol Biol. 2009;471:85–105.
- Adjei Boakye E, Grubb L, Peterson CE, Osazuwa-Peters N, Grabosch S, Ladage HD, et al. Risk of second primary cancers among survivors of gynecological cancers. Gynecol Oncol. 2020;158(3):719–726. doi:https://doi.org/10.1016/j.ygyno.2020.06.492.
- Xu J, Peng J-J, Yang W, Fu K, Zhang Y. Vaginal microbiomes and ovarian cancer: a review. Am J Cancer Res. 2020;10:743–756.
- Bray F, Laversanne M, Weiderpass E, Arbyn M. Geographic and temporal variations in the incidence of vulvar and vaginal cancers. Int J Cancer. 2020;147(10):2764–2771. doi:https://doi.org/10.1002/ijc.33055.
- Mehnert WH, Haas JF, Kittelmann B, Staneczek W, Möhner M, Kaldor JM, et al. A case-control study of leukaemia as a second primary malignancy following ovarian and breast neoplasms. IARC Sci Publ. 1986;(78):203–21.
- Levi F, Randimbison L, Blanc-Moya R, La Vecchia C. Second neoplasms after invasive and borderline ovarian cancer. Eur J Cancer Prev. 2009;18(3):216–219. doi:https://doi.org/10.1097/CEJ.0b013e3283240474.
- Shenolikar R, Durden E, Meyer N, Lenhart G, Moore K. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States. Gynecol Oncol. 2018;151(2):190–195. doi:https://doi.org/10.1016/j.ygyno.2018.09.003.
- Li M, Chai H-F, Peng F, Meng Y-T, Zhang L-Z, Zhang L, et al. Estrogen receptor β upregulated by lncRNA-H19 to promote cancer stem-like properties in papillary thyroid carcinoma. Cell Death Dis. 2018;9(11):1120. doi:https://doi.org/10.1038/s41419-018-1077-9.
- Hoffmann M, Gogola J, Ptak A. Apelin abrogates the stimulatory effects of 17β-estradiol and insulin-like growth factor-1 on proliferation of epithelial and granulosa ovarian cancer cell lines via crosstalk between APLNR and ERα/IGF1R. Mol Biol Rep. 2019;46(6):6325–6338. doi:https://doi.org/10.1007/s11033-019-05073-2.
- Donin N, Filson C, Drakaki A, Tan H-J, Castillo A, Kwan L, et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer. 2016;122(19):3075–3086. doi:https://doi.org/10.1002/cncr.30164.
- Casper AC, Parsons MW, Chipman J, Burt LM, Jr., Suneja G, Maurer KA, et al. Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up. Gynecol Oncol. 2021;162(2):454–460. doi:https://doi.org/10.1016/j.ygyno.2021.05.034.
- Wood M, Vogel V, Ng A, Foxhall L, Goodwin P, Travis L. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol. 2012;30(30):3734–3745. doi:https://doi.org/10.1200/JCO.2012.41.8681.
- De Luca A, Frusone F, Vergine M, Cocchiara R, La Torre G, Ballesio L, et al. Breast cancer and multiple primary malignant tumors: case report and review of the literature. In Vivo. 2019;33(4):1313–1324. doi:https://doi.org/10.21873/invivo.11605.
- Marcheselli R, Marcheselli L, Cortesi L, Bari A, Cirilli C, Pozzi S, et al. Risk of second primary malignancy in breast cancer survivors: a nested population-based case-control study. J Breast Cancer. 2015;18(4):378–385. doi:https://doi.org/10.4048/jbc.2015.18.4.378.
- Moore EK, Roylance R, Rosenthal AN. Breast cancer metastasising to the pelvis and abdomen: what the gynaecologist needs to know. BJOG. 2012;119(7):788–794. doi:https://doi.org/10.1111/j.1471-0528.2012.03314.x.
- Reimer RR, Hoover R, Fraumeni JF, Young RC. Second primary neoplasms following ovarian cancer. J Natl Cancer Inst. 1978;61(5):1195–1197. doi:https://doi.org/10.1093/jnci/61.5.1195.
- Bouchardy C, Fernandez S, Merglen A, Usel M, Fioretta G, Rapiti E, et al. Increased risk of second cancer among patients with ovarian borderline tumors. Gynecol Oncol. 2008;109(2):210–214. doi:https://doi.org/10.1016/j.ygyno.2008.01.032.
- Travis LB, Curtis RE, Boice JD, Platz CE, Hankey BF, Fraumeni JF. Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Res. 1996;56(7):1564–1570.
- Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12(1):20–37. doi:https://doi.org/10.1634/theoncologist.12-1-20.
- Nguyen JMV, Vicus D, Nofech-Mozes S, Gien LT, Bernardini MQ, Rouzbahman M, et al. Risk of second malignancy in patients with ovarian clear cell carcinoma. Int J Gynecol Cancer. 2021;31(4):545–552. doi:https://doi.org/10.1136/ijgc-2020-001946.
- Yang Q, Wu Z, He X, Yu L, Zhang X, Lei K. Thyroid cancer benefits the prognosis of ovarian cancer: a SEER-based study. Adv Ther. 2019;36(5):1211–1220. doi:https://doi.org/10.1007/s12325-019-00918-5.
- Faehling M, Schwenk B, Kramberg S, Fallscheer S, Leschke M, Sträter J, et al. Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practice. J Cancer Res Clin Oncol. 2018;144(10):2059–2066. doi:https://doi.org/10.1007/s00432-018-2714-5.
- Wang K, Mei F, Wu S, Tan Z. Hemangiopericytoma: incidence, treatment, and prognosis analysis based on SEER database. Biomed Res Int. 2020;2020:2468320.
- Wang X, Li X, Su S, Liu M. Marital status and survival in epithelial ovarian cancer patients: a SEER-based study. Oncotarget. 2017;8(51):89040–89054. doi:https://doi.org/10.18632/oncotarget.21648.
- Luo P, Zhou J-G, Jin S-H, Qing M-S, Ma H. Influence of marital status on overall survival in patients with ovarian serous carcinoma: finding from the surveillance epidemiology and end results (SEER) database. J Ovarian Res. 2019;12(1):126. doi:https://doi.org/10.1186/s13048-019-0600-7.